The goal is not simply being lighter
Ongoing research is exploring these issues and looking at combining GLP-1 agonists and dual agonists with other treatments for more comprehensive weight management[2][4]
Semaglutide was originally designed for the treatment of type 2 diabetes, but its also used to help patients lose weight in conjunction with a balanced diet and regular physical activity
Furthermore, a real-world retrospective study comparing the compliance of patients receiving different GLP-1RAs for the treatment of hyperglycemic found that even if GLP-1RA weekly preparations were used, there were still differences in compliance [171]
In the present investigation, rats administered Genta displayed indications of kidney toxicity, as indicated by an increase in relative kidney weight, elevated serum Cr, BUN, Cyst-c, and urine GGT levels, and a reduction in Cr Cl